Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC

Programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade is currently widely used in the treatment of metastatic NSCLC. Despite available biomarker stratification, clinical responses vary. Thus, the search for novel biomarkers with improved response prediction is ongoing...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2021-08, Vol.16 (8), p.1349-1358
Main Authors: Yeong, Joe, Suteja, Lisda, Simoni, Yannick, Lau, Kah Weng, Tan, Aaron C., Li, Hui Hua, Lim, Sherlly, Loh, Jie Hua, Wee, Felicia Y.T., Nerurkar, Sanjna Nilesh, Takano, Angela, Tan, Eng Huat, Lim, Tony K.H., Newell, Evan W., Tan, Daniel S.W.
Format: Article
Language:English
Subjects:
Apoptosis Regulatory Proteins
B7-H1 Antigen
Biomarkers, Tumor - genetics
CD39
CD8-Positive T-Lymphocytes
Humans
Immunofluorescence
Immunotherapy
Lung cancer
Lung Neoplasms - drug therapy
Programmed Cell Death 1 Receptor
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade is currently widely used in the treatment of metastatic NSCLC. Despite available biomarker stratification, clinical responses vary. Thus, the search for novel biomarkers with improved response prediction is ongoing. Previously, using mass cytometry or cytometry by time-of-flight (CyTOF), our group demonstrated that CD39+CD8+ immune cells represent tumor antigen-specific, cytotoxic T cells in treatment-naive NSCLC. We hypothesized that accurate quantitation of this T cell subset would predict immunotherapy outcome. To translate this to a clinical setting, the present study compared CyTOF data with a range of clinically relevant methods, including conventional immunohistochemistry (IHC), multiplex IHC or immunofluorescence (mIHC), and gene expression assay by NanoString. Quantification using mIHC but not conventional IHC or NanoString correlated with the CyTOF results. The specificity and sensitivity of mIHC were then evaluated in a separate retrospective NSCLC cohort. CD39+CD8+ T cell proportion, as determined by mIHC, successfully stratified responders and nonresponders to PD-1 or PD-L1 inhibitors (objective response rate of 63.6%, compared with 0% for the negative group). This predictive capability was independent from other confounding factors, such as total CD8+ T cell proportion, CD39+ lymphocyte proportion, PD-L1 positivity, EGFR mutation status, and other clinicopathologic parameters. Our results suggest that the mIHC platform is a clinically relevant method to evaluate CD39+CD8+ T cell proportion and that this marker can serve as a potential biomarker that predicts response to PD-1 or PD-L1 blockade in patients with NSCLC. Further validation in additional NSCLC cohorts is warranted.
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2021.04.016